Does Rallies show 13F holders for TNGX?

Yes. Rallies tracks hedge fund and 13F ownership data for TNGX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TNGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TNGX. It does not provide personalized investment advice.

TNGX (Tango Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Tango Therapeutics, Inc. (TNGX) is a publicly traded Healthcare sector company. As of May 21, 2026, TNGX trades at $22.26 with a market cap of $2.98B and a P/E ratio of -24.47. TNGX moved +3.69% today. Year to date, TNGX is +136.59%; over the trailing twelve months it is +918.36%. Its 52-week range spans $1.03 to $28.41. Analyst consensus is strong buy with an average price target of $30.70. Rallies surfaces TNGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TNGX stock?

Hedge funds tracked by Rallies that own TNGX include Farallon Capital, Orbimed Advisors, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tango Therapeutics, Inc..

TNGX Key Metrics

Key financial metrics for TNGX
Metric	Value
Price	$22.26
Market Cap	$2.98B
P/E Ratio	-24.47
EPS	$-0.87
Dividend Yield	0.00%
52-Week High	$28.41
52-Week Low	$1.03
Volume	198
Avg Volume	0
Revenue (TTM)	$62.38M
Net Income	$-101.59M
Gross Margin	0.00%

Top Hedge Funds Holding TNGX

Farallon Capital holds 9.10M shares of TNGX, changed -30.35% as of Mar 31, 2026.
Orbimed Advisors holds 550.00K shares of TNGX, changed +0.00% as of Mar 31, 2025.
Mangrove Partners holds 12.56K shares of TNGX, changed +0.00% as of Mar 31, 2026.

Latest TNGX News

Tango Therapeutics Reports $379.8 M Cash Runway, Q1 Net Loss of $45.5 M — May 13, 2026
Tango Therapeutics Names CFO, Operations and Strategy Heads to Advance Vopimetostat — Apr 15, 2026
Tango Therapeutics Stock Soars 36.3% on Erasca Collaboration for MTAP-Deleted Cancer Study — Mar 6, 2026
Tango Therapeutics Climbs 36% to $16.97 on Stifel Buy Rating — Mar 6, 2026
Tango Therapeutics Forecasts Q4 Revenue at $0.5M, Cuts 2026 Outlook 32% — Mar 4, 2026

Recent TNGX Insider Trades

Crystal Adam sold 25.90K (~$548.90K) on May 1, 2026.
Crystal Adam sold 1.10K (~$24.20K) on May 1, 2026.
Crystal Adam sold 38.46K (~$961.50K) on Apr 15, 2026.

TNGX Analyst Consensus

10 analysts cover TNGX: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.70.

Common questions about TNGX

Who owns TNGX stock?: Hedge funds tracked by Rallies that own TNGX include Farallon Capital, Orbimed Advisors, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tango Therapeutics, Inc..
Does Rallies show 13F holders for TNGX?: Yes. Rallies tracks hedge fund and 13F ownership data for TNGX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TNGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TNGX. It does not provide personalized investment advice.